In Vitro Antibacterial Activity of Norfloxacin (MK-0366, AM-715) and Other Agents Against Gastrointestinal Tract Pathogens

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1983 Jan 1

PMID 6219622

Citations 20

Authors

D L Shungu

E Weinberg

H H GADEBUSCH

Affiliations

Soon will be listed here.

Abstract

A comparison was made of the in vitro activities of norfloxacin and of nine other orally administered antibacterial agents against 180 clinical isolates representing the bacterial species most frequently implicated in infections of the gastrointestinal tract in humans. The 90% minimal inhibitory concentrations showed norfloxacin to be 4, 15, 4, 17, 17, 17, and 33 times more active than the next best compound tested against Campylobacter fetus subsp. jejuni, Escherichia coli, Salmonella spp., Shigella spp., Vibrio cholerae, Vibrio parahaemolyticus, and Yersinia enterocolitica, respectively, with an overall 90% minimal inhibitory concentration of less than or equal to 0.5 micrograms/ml. Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml). These results should encourage further evaluation of norfloxacin as a potential chemotherapeutic agent in the treatment of enteric bacterial infections for which antibiotic therapy is indicated.

Citing Articles

Epidemiology and Control of Strawberry Bacterial Angular Leaf Spot Disease Caused by Xanthomonas fragariae.

Kim D, Gang G, Jeon C, Kang N, Lee S, Kwak Y Plant Pathol J. 2016; 32(4):290-9.

PMID: 27493604 PMC: 4968639. DOI: 10.5423/PPJ.OA.01.2016.0007.

Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants.

Okuda J, Hayakawa E, Nishibuchi M, Nishino T Antimicrob Agents Chemother. 1999; 43(5):1156-62.

PMID: 10223929 PMC: 89126. DOI: 10.1128/AAC.43.5.1156.

Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

Goodman L, Fliegelman R, Trenholme G, Kaplan R Antimicrob Agents Chemother. 1984; 25(4):504-6.

PMID: 6732220 PMC: 185564. DOI: 10.1128/AAC.25.4.504.

In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Eliopoulos G, Gardella A, Moellering Jr R Antimicrob Agents Chemother. 1984; 25(3):331-5.

PMID: 6721464 PMC: 185510. DOI: 10.1128/AAC.25.3.331.

Comparison of the in vitro activity of ciprofloxacin (Bay o 9867) and norfloxacin against gastrointestinal tract pathogens.

Gutierrez-Altes A Eur J Clin Microbiol. 1984; 3(4):367.

PMID: 6237905 DOI: 10.1007/BF01977497.

References

Clark H, Brown N, Wallace J, Turck M . Emergence of resistant organisms as a function of dose in oxolinic acid therapy. Am J Med Sci. 1971; 261(3):145-8. DOI: 10.1097/00000441-197103000-00003. View

HALTALIN K, Nelson J, Kusmiesz H . Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch Dis Child. 1973; 48(4):305-12. PMC: 1648332. DOI: 10.1136/adc.48.4.305. View

DuPont H, Hornick R . Clinical approach to infectious diarrheas. Medicine (Baltimore). 1973; 52(4):265-70. View

Gordon R, Thompson T, CARLSON W, Dyke J, Stevens L . Antimicrobial resistance of Shigellae isolated in Michigan. JAMA. 1975; 231(11):1159-61. View

Byers P, DuPont H, Goldschmidt M . Antimicrobial susceptibilities of shigellae isolated in Houston, Texas, in 1974. Antimicrob Agents Chemother. 1976; 9(2):288-91. PMC: 429516. DOI: 10.1128/AAC.9.2.288. View

Burman L . Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria. J Antimicrob Chemother. 1977; 3(5):509-16. DOI: 10.1093/jac/3.5.509. View

Ribner B, FREIMER E . Oxolinic acid for the treatment of chronic gastrointestinal Shigella carriers. Am J Trop Med Hyg. 1978; 27(4):840-2. DOI: 10.4269/ajtmh.1978.27.840. View

Farrar Jr W . Antibiotic resistance in intestinal bacteria. Clin Gastroenterol. 1979; 8(3):803-26. View

Lambert H . Antimicrobial agents in diarrhoeal disease. Clin Gastroenterol. 1979; 8(3):827-33. View

10.

Sutter V, Barry A, Wilkins T, Zabransky R . Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother. 1979; 16(4):495-502. PMC: 352888. DOI: 10.1128/AAC.16.4.495. View

11.

Ito A, Hirai K, Inoue M, Koga H, SUZUE S, IRIKURA T . In vitro antibacterial activity of AM-715, a new nalidixic acid analog. Antimicrob Agents Chemother. 1980; 17(2):103-8. PMC: 283741. DOI: 10.1128/AAC.17.2.103. View

12.

Dornbusch K, Gezelius L . Susceptibility testing to trimethoprim alone and combined with sulphonamides. Chemotherapy. 1980; 26(6):418-26. DOI: 10.1159/000237937. View

13.

Sleijfer D, Mulder N, de Vries-Hospers H, Fidler V, NIEWEG H, Van Der Waaij D . Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1965). 1980; 16(6):859-69. DOI: 10.1016/0014-2964(80)90140-1. View

14.

Bachrach S . Successful treatment of an institutional outbreak of shigellosis. Clin Pediatr (Phila). 1981; 20(2):127-31. DOI: 10.1177/000992288102000207. View

15.

Kronborg I, Howard A . Diarrhoea: causes and specific treatment. Drugs. 1981; 21(1):62-8. DOI: 10.2165/00003495-198121010-00004. View

16.

Hirai K, Ito A, Abe Y, SUZUE S, IRIKURA T, Inoue M . Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother. 1981; 19(1):188-9. PMC: 181380. DOI: 10.1128/AAC.19.1.188. View

17.

Khan M, Siddiqui Y, Gruninger R . Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1981; 20(2):265-6. PMC: 181677. DOI: 10.1128/AAC.20.2.265. View

18.

JUHLIN I, Winblad S . Susceptibility to mecillinam and other antibiotics of 28 O-serotypes of Yersinia enterocolitica. J Antimicrob Chemother. 1981; 8(4):291-7. DOI: 10.1093/jac/8.4.291. View

19.

Murray B, Rensimer E, DuPont H . Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med. 1982; 306(3):130-5. DOI: 10.1056/NEJM198201213060302. View

20.

King A, Warren C, Shannon K, Phillips I . In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother. 1982; 21(4):604-7. PMC: 181950. DOI: 10.1128/AAC.21.4.604. View